Table 1.
Effects of SGLT2 inhibitors on cardiovascular events.
| Empagliflozin | Canagliflozin | Dapagliflozin | |
|---|---|---|---|
| 3point MACE | Sinificantly desirerable | N.S. | N.S. |
| Primary 3poin MACE | N.D. | Sinificantly desirerable | N.D. |
| CV death | Sinificantly desirerable | N.S. | N.S. |
| HHF | Sinificantly desirerable | Sinificantly desirerable | Sinificantly desirerable |
| non-fatal MI | N.S. | N.S. | N.S. |
| non-fatal stroke | N.S. | N.S. | N.S. |
| Primary HHF | N.D. | N.D. | Sinificantly desirerable |
| Pre-MI history | N.D. | Sinificantly desirerable | N.S. |
| Reference No. | 9 | 10, 12 | 11, 13 |
N.S.: not significantN.D.: not determined; HHF: hospitalization for heart failure; MI: myocardial infarction.